Vol 7, Supplement 2 (April 23, 2018): Translational Lung Cancer Research

Nivolumab in pretreated non-small cell lung cancer: continuing the immunolution

Massimiliano Salati, Cinzia Baldessari, Bruna Cerbelli, Andrea Botticelli

PDF Pages: S91-S94 Full Text (2393) Open Access

Companion and complementary diagnostics for first-line immune checkpoint inhibitor treatment in non-small cell lung cancer

Jan Trøst Jørgensen, Karsten Bork Nielsen

PDF Pages: S95-S99 Full Text (3507) Open Access

Dacomitinib in EGFR-positive non-small cell lung cancer: an attractive but broken option

Antonio Passaro, Filippo de Marinis

PDF Pages: S100-S102 Full Text (3399) Open Access

Lorlatinib in ALK- and ROS1-positive NSCLC: the future has a start

Francesco Facchinetti, Luc Friboulet

PDF Pages: S103-S106 Full Text (3676) Open Access

Stage III non-small cell lung cancer: escalation matters, but how?

Aparna Madhukeshwar Hegde, Paul Raymond Walker

PDF Pages: S107-S110 Full Text (1695) Open Access

A promising result of locoregional tumor control with biologically adaptive radiotherapy in patients with locally advanced non-smallcell lung cancer

Yukinori Matsuo

PDF Pages: S111-S113 Full Text (1584) Open Access

Patient selection for future lung cancer computed tomography screening programmes: lessons learnt post National Lung Cancer Screening Trial

John K. Field, Stephen W. Duffy, David R. Baldwin

PDF Pages: S114-S116 Full Text (1568) Open Access

Repurposing established cyclic adenosine monophosphate reducing agents for the prevention and therapy of epidermal growth factor receptor inhibitor resistance in non-small cell lung cancer

Hildegard M. Schuller

PDF Pages: S117-S122 Full Text (1565) Open Access

Stressing the need to overcome EGFR tyrosine kinase inhibitor resistance

Leila Toulabi, Bríd M. Ryan

PDF Pages: S123-S126 Full Text (1392) Open Access

First line osimertinib for the treatment of patients with advanced EGFR-mutant NSCLC

Biagio Ricciuti, Rita Chiari

PDF Pages: S127-S130 Full Text (1743) Open Access

No room for statins in the quest for survival benefits in small cell lung cancer

Francesco Facchinetti, Marcello Tiseo

PDF Pages: S131-S133 Full Text (1215) Open Access

The evolving first-line treatment of advanced non-small cell lung cancer harbouring epidermal growth factor receptor mutations

Lore Decoster, Philippe Giron, Sacha Mignon, Jacques De Grève

PDF Pages: S134-S137 Full Text (1644) Open Access

Patient-related outcomes with the use of checkpoint inhibitors for the treatment of metastatic non-small cell lung cancer

Jyoti Malhotra, Salma K. Jabbour

PDF Pages: S138-S141 Full Text (1535) Open Access

EGFR targeted therapy for lung cancer: are we almost there?

Giulio Metro

PDF Pages: S142-S145 Full Text (1485) Open Access

Precision radiotherapy for patients with locally advanced non-small cell lung cancer in the era of immunotherapy and precision medicine

Hidehito Horinouch

PDF Pages: S146-S148 Full Text (1429) Open Access

Quality of life for non-small cell lung cancer patients in the age of immunotherapy

Robert A. Ramirez, Jonathan Lu, Katharine E. H. Thomas

PDF Pages: S149-S152 Full Text (4490) Open Access

Durvalumab for non-resectable stage IIIB non-small cell lung cancer—a small step or a big leap?

Wolfram C. M. Dempke, Klaus Fenchel

PDF Pages: S153-S157 Full Text (1885) Open Access

Editorial commentary: meeting a paramount challenge

Ping Yang

PDF Pages: S158-S159 Full Text (1255) Open Access

Can we use interleukin-1β blockade for lung cancer treatment?

Adrian Gottschlich, Stefan Endres, Sebastian Kobold

PDF Pages: S160-S164 Full Text (2432) Open Access

Osimertinib in untreated epidermal growth factor receptor (EGFR)- mutated advanced non-small cell lung cancer

Vanesa Gregorc, Chiara Lazzari, Niki Karachaliou, Rafael Rosell, Mariacarmela Santarpia

PDF Pages: S165-S170 Full Text (2804) Open Access

Post-operative radiation therapy in locally advanced non-small cell lung cancer and the impact of sequential versus concurrent chemotherapy

Mark R. Waddle, Stephen Ko, Margaret M. Johnson, Yanyan Lou, Robert C. Miller, Anna C. Harrell, Daniel M. Trifiletti

PDF Pages: S171-S175 Full Text (1730) Open Access

The continued EGFR-TKI with cytotoxic chemotherapy at progression—poison or medicine?

Shin-Kyo Yoon, Chang Min Choi, Jae Cheol Lee

PDF Pages: S176-S178 Full Text (1759) Open Access

Adjuvant bevacizumab for resected non-small cell lung cancer: the end of an era?

Giannis Mountzios

PDF Pages: S179-S182 Full Text (1784) Open Access